Fri Aug 29 17:57:47 SGT 2014  
HEPATITIS
B
    Hepatitis B, Philippines
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Hepatitis B, Philippines

Summary

Hepatitis B, Philippines @hepatitisb_biz: Hepatitis B symptoms in men/women, screening/diagnosis, testing/check and treatment, Philippines - Private and confidential service.

Keywords: Hepatitis B Philippines, Philippines Hepatitis B, Hepatitis B.

Description

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
HIV STD TESTING TREATMENT™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Hepatitis B, Philippines
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Budget airlines based in Singapore:

Budget airlines operating in Singapore:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

Location reference


Latest News

The global burden of liver disease: The major impact of China
Thu, 28 Aug 2014 21:01:15 +0100 | Hepatology
Abstract

Hepatitis B Infection: Molecular Mechanisms and Pathogenesis
Thu, 28 Aug 2014 18:56:22 +0100 | Viral Immunology
Viral Immunology Sep 2014, Vol. 27, No. 7: 319-320. (Source: Viral Immunology)

Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: A nested case‐control study
Thu, 28 Aug 2014 00:00:00 +0100 | Hepatology
Conclusion: In this prospective study on western European populations, serum levels of 25(OH)D were inversely associated with the risk of HCC. Given the rising incidence of this cancer in low‐risk developed countries and the strong public health interest surrounding the potentially cancer‐protective roles of vitamin D, additional studies in different populations are required. (Hepatology 2014) (Source: Hepatology)

Entecavir Is Safe and Effective in Patients Previously Treated with Adefovir, including Those with Adefovir‐Resistance
Thu, 28 Aug 2014 00:00:00 +0100 | Journal of Gastroenterology and Hepatology
ConclusionsIn ADV‐experienced patients, high rates of CVS and BR can be achieved/sustained after switching to ETV, including those with ADV resistance or with prior exposure to LAM. (Source: Journal of Gastroenterology and Hepatology)

Long‐term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B
Thu, 28 Aug 2014 00:00:00 +0100 | Journal of Gastroenterology and Hepatology
ConclusionsLong‐term lamivudine therapy achieves regression of fibrosis/cirrhosis, improvement of histological and disease progression in AdLF‐CHB patients. (Source: Journal of Gastroenterology and Hepatology)

Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria, 2010–2011
Wed, 27 Aug 2014 00:00:00 +0100 | Journal of Medical Virology
Viral hepatitis, particularly hepatitis B and C, are diseases with worldwide distribution that present a significant public health problem. Seroprevalence studies allow assessment of the extent of the disease burden, the identification of populations at risk and the monitoring trends over time. A multi‐center seroprevalence study, carried out in Bulgaria (covering the five largest cities – Sofia, Plovdiv, Varna, Pleven, and Stara Zagora) in 1999–2000 estimated a crude seroprevalence rate of 3.9% for HBsAg and 1.3% for anti‐HCV. A decade later, comparable rates were observed in a study including 865 outpatients consulting a clinical laboratory in Plovdiv, the second largest administrative region in Bulgaria. The crude seroprevalence rate measured for hepatitis B (HBsAg) was 3.9%. Th...

Direct role of antibody‐secreting B cells in the severity of chronic hepatitis B
Wed, 27 Aug 2014 00:00:00 +0100 | Journal of Medical Virology
In this study, the number of plaque forming cells [PFC‐(IgG, IgM, anti‐HBc IgG, and anti‐HBc IgM)], liver function tests (LFT) [alkaline phosphatase (ALP), alanine aminotransferase (ALT), and total serum bilirubin (TSB)], the levels of IL‐10 in sera and in lymphocyte cultures, the number of CD4+ and CD8+ cells were measured in the peripheral blood of patients and in the controls. In addition, the hepatocytotoxic effect of anti‐HBc and anti‐HBe in vitro was studied. The largest number of PFCs was observed in the peripheral blood of patients with chronic hepatitis B. This was concomitant with a decrease in CD4+/CD8+ ratio versus this ratio in asymptomatic HBV carriers and in healthy volunteers (P < 0.05). An increase in immunoglobulin (IgG and IgM) levels, anti‐HBc IgG, ...

Mutations associated with occult hepatitis B in HIV‐positive South Africans
Wed, 27 Aug 2014 00:00:00 +0100 | Journal of Medical Virology
In this study, sera from 394 HIV‐positive South Africans were tested for HBV DNA and HBsAg. For patients with detectable HBV DNA, the overlapping surface and polymerase open reading frames (ORFs) were sequenced. Occult‐associated mutations—those mutations found exclusively in individuals with occult HBV infection but not in individuals with chronic HBV infection from the same cohort or GenBank references—were identified. Ninety patients (22.8%) had detectable HBV DNA. Of these, 37 had detectable HBsAg, while 53 lacked detectable surface antigen. The surface and polymerase ORFs were cloned successfully for 19 patients with chronic HBV and 30 patients with occult HBV. In total, 235 occult‐associated mutations were identified. Ten occult‐associated mutations were identified in mor...

MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1
Wed, 27 Aug 2014 00:00:00 +0100 | Carcinogenesis
Hepatitis B virus surface antigen (HBsAg) is an important risk factor for hepatocellular carcinoma (HCC) and is downregulated during hepatocarcinogenesis. MicroRNAs (miRNAs) are frequently deregulated in HCC tissues. However, whether the deregulation of certain miRNAs in HCC has an impact on HBsAg expression remains unclear. We found here that microRNA-581 (miR-581), which is deregulated during hepatocarcinogenesis, promoted HBsAg expression. Additionally, miR-581 targeted Dicer and endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 1 (EDEM1) and repressed their expression. Although Dicer cannot process HBV transcripts, Dicer knockdown led to increased HBsAg secretion, most likely due to a reduction in the levels of Dicer-processed 7SL RNA fragments. Moreover, Dicer...

Active co‐infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy
Tue, 26 Aug 2014 20:55:10 +0100 | Journal of Medical Virology
ABSTRACT